Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
Konecny
Gottfried E
GE
Wilson
Cindy A
CA
Slamon
Dennis J
DJ
D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D004791:Enzyme Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib